Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atai Life Sciences N.V. (NQ: ATAI )

1.671 +0.081 (+5.08%)
Streaming Delayed Price Updated: 9:37 AM EDT, Jul 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 89,341
Open 1.620
Bid (Size) 1.670 (7)
Ask (Size) 1.680 (29)
Prev. Close 1.590
Today's Range 1.620 - 1.680
52wk Range 1.025 - 2.850
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
3 Dirt-Cheap Drug Developers With Blockbuster Potential
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent. 
Via InvestorPlace

Performance

YTD
-1.14%
-1.14%
1 Month
+25.62%
+25.62%
3 Month
-15.19%
-15.19%
6 Month
-14.76%
-14.76%
1 Year
-20.06%
-20.06%

More News

Read More
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
Via InvestorPlace
3 Psychedelic Stocks to Ride to the Moon and Beyond
Via InvestorPlace
Exposures Product Safety
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
Via InvestorPlace
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
Via InvestorPlace
Clinical-Stage BioTech Drug Stocks Declined 13% In June
Via Talk Markets
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
From atai Life Sciences
Via GlobeNewswire
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Via Talk Markets
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
From atai Life Sciences
Via GlobeNewswire
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
Via Talk Markets
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
Via Benzinga
Exposures Product Safety
What's Going On With MindMed And Psychedelic Stocks?
Via Benzinga
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
From atai Life Sciences
Via GlobeNewswire
ATAI Stock Earnings: ATAI Life Sciences Beats EPS for Q1 2024
Via InvestorPlace
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
From atai Life Sciences
Via GlobeNewswire
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Via Benzinga
Topics Cannabis
Exposures Cannabis
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
Via Talk Markets
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Via Talk Markets
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
Via Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
From atai Life Sciences
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.